The observation of Buttle and his associates1 that sulfanilamide protected and cured mice of an experimentally induced meningococcic septicemia has been amply confirmed by Proom,2 Rosenthal and his associates,3 Levaditi and Vaisman4 and Brown.5 Branham and Rosenthal3 and Brown5 concluded as a result of their observations on experimental meningococcic infections in mice that a combination of sulfanilamide with an effective antimeningococcus serum produced a greater protective or therapeutic effect than either of the agents by itself. Schwentker, Gelman and Long6 in a preliminary report considered sulfanilamide to be as effective in the treatment of meningococcic infections in human beings as good specific antiserums. All of their eleven patients with but one exception were treated by both the parenteral and the intrathecal route. In this group of eleven patients there was but one death.
Since this report was published, McIntosh and his co-workers,
WAGHELSTEIN JM. SULFANILAMIDE IN THE TREATMENT OF 106 PATIENTS WITH MENINGOCOCCIC INFECTIONS. JAMA. 1938;111(24):2172–2174. doi:10.1001/jama.1938.02790500010003
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: